Download Cyclin Dependent Kinase Inhibition Leads to Cell Death in Triple

Cyclin Dependent Kinase Inhibition Leads to Cell Death in Triple Negative Breast Cancer
Nathan James
Mentor: Kai Kessenbrock
Triple negative breast cancer (TNBC) is a severe form of breast cancer in which the cancer cells lack estrogen,
progesterone, and human epidermal growth factor receptors. These receptors typically provide a target for
therapeutic treatment of the disease, thus the lack of receptors prevents effective treatment. One strategy to
treat TNBC is through the use of Cyclin Dependent Kinase (CDK) inhibitors, which could result in cell death
through apoptosis in rapidly dividing cells. We found that Dinaciclib, a CDK inhibitor, inhibited proliferation
similarly in both TNBC and receptor positive breast cancer (RPBC), and increased cell death in the TNBC
cell line, but did not inhibit cell migration in TNBC.